Dr. Braunschweig on Mitigating the Toxicities of CAR T-Cell Therapy in Lymphoma

Video

Ira Braunschweig, MD, discusses mitigating ​the toxicities that are associated with CAR T-cell therapy in lymphoma.

Ira Braunschweig, MD, director, Stem Cell Transplant Program, clinical program director, Hematologic Malignancies, Montefiore Medical Center, associate professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discusses mitigating ​the toxicities that are associated with CAR T-cell therapy in lymphoma.

Despite the encouraging responses that have been observed with CAR T-cell therapy in lymphoma, several toxicities ​can arise with these products.

However, data suggests that ​administration of the immunosuppressive agent tocilizumab (Actemra) at fever onset could help mitigate some of the adverse effects, such as cytokine release syndrome, says Braunschweig. Notably, this agent will not abrogate the anti-tumor effect of the cellular therapy. 

Furthermore, ​data have shown that ​early steroid use may mitigate neurotoxicity, Braunschweig adds. ​Using steroids, which kill lymphocytes, may seem counterintuitive as CAR T cells are lymphocytes. However,​ steroids appear to mitigate neurotoxicity without alter​ing the mechanism of​ action of the​ CAR T-cell therapy.

Utilizing steroids early may eliminate the risk of confusion or, in severe cases, coma, among patients with lymphoma who receive CAR T-cell therapy, Braunschweig concludes.

Recent Videos
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.